CORRECTION article

Front. Microbiol., 11 August 2025

Sec. Antimicrobials, Resistance and Chemotherapy

Volume 16 - 2025 | https://doi.org/10.3389/fmicb.2025.1646639

Correction: Anti-MRSA activities of enterocins DD28 and DD93 and evidences on their role in the inhibition of biofilm formation

  • 1. Université de Lille 1 Sciences et Technologies - Institut Charles Viollette, Lille, France

  • 2. Hôpital Victor Provo de Roubaix, Roubaix, France

  • 3. Institut d'Electronique, de Microélectronique et de Nanotechnologie, UMR CNRS 8520, Université Lille 1, Lille, France

Article metrics

View details

1

Citations

744

Views

167

Downloads

There was a mistake in Figure 4 as published. A wrong figure appeared.

The corrected Figure 4 and it's caption appear below.

Figure 4

A series of fluorescent microscopy images showing bacterial growth over time with different treatments. The grid shows images at 0, 3, 6, and 24 hours for each treatment: control, erythromycin, ofloxacin, DD28, DD93, erythromycin with DD28, rifampin, and vancomycin. Each row represents a different time point, displaying variations in bacterial growth and fluorescence intensity.

Biofilms formation by MRSA-S1 on AISI 304L stainless steel slides conditioned with antimicrobial agents for 2 h and then washed and inoculated with 2 ml of 107 CFU/ml MRSA-S1 culture before removing, washing and adding TSB-YE medium for 0, 3, 6, and 24 h of incubation at 37°C. Concentrations of antimicrobial agents used were 8 mg/L for erythromycin, 0.03 mg/L for rifampin, 200 mg/L for enterocin DD28, 50 mg/L + 1 mg/L for enterocin DD28 + erythromycin, respectively. Biofilms were stained with the BacLight Live/Dead Viability Kit and imaged by epifluorescence microscopy after staining pattern for live cells (green) and dead cells (red). The experiments were performed at least twice and representative images are shown.

The original version of this article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

enterocins, antibiotics, MRSA, synergism, bacteriocins

Citation

Al Atya AK, Belguesmia Y, Chataigne G, Ravallec R, Vachée A, Szunerits S, Boukherroub R and Drider D (2025) Correction: Anti-MRSA activities of enterocins DD28 and DD93 and evidences on their role in the inhibition of biofilm formation. Front. Microbiol. 16:1646639. doi: 10.3389/fmicb.2025.1646639

Received

13 June 2025

Accepted

28 July 2025

Published

11 August 2025

Volume

16 - 2025

Edited and reviewed by

Rustam Aminov, University of Aberdeen, United Kingdom

Updates

Copyright

*Correspondence: Djamel Drider

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics